BioSpace News Archive

Oral Presentation of Clinical Data for TIL in Combination with Pembrolizumab in Immune-Checkpoint Inhibitor Naïve Patients with Advanced Cancers Poster for TIL Therapy in Advanced, Immune Checkpoint Inhibitor-Treated Non-Small Cell Lung Cancer (NSCLC)

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the first patient has been enrolled in the company’s Phase 2b study evaluating the safety and efficacy of NUZYRA ® (omadacycline) for the treatment for nontuberculous mycobacterial (NTM) pulmonary disease

PPD, Inc. will host a conference call on Thursday, October 28, 2021, at 8 a.m. (U.S. Eastern Time) to discuss its third quarter 2021 financial results.

OpGen, Inc. today announced the closing of its previously announced registered direct offering with a single healthcare-focused institutional investor of 150,000 shares of convertible preferred stock

Amendment to ongoing collaboration allows Wave to advance or partner CNS programs, including those using ADAR editing Takeda option to co-develop and co-commercialize late-stage CNS programs, including clinical programs WVE-004 and WVE-003, remains unchanged

Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 115,000 shares of Dynavax common stock as inducements to 1 newly-hired employee in connection with commencement of employment with the Company.

Zoetis Inc. (NYSE:ZTS) today announced the appointment of Robert J. Polzer, PhD, as Executive Vice President and President of Research & Development for the company, effective Jan. 1, 2022.

ViewRay, Inc. (Nasdaq: VRAY) announced today that the company will host a Virtual Clinical Data Event for Investors and Analysts on Thursday, October 28, 2021 . The event will begin at 8:30 am ET / 5:30 am PT .

During its annual R&D investment briefing earlier today, CSL Limited (ASX:CSL; USOTC:CSLLY) highlighted progress from its novel pipeline that spans six therapeutic areas (immunology, hematology, respiratory, cardiovascular and metabolic, transplant, influenza), four scientific platforms (plasma fractionation, recombinant technology, cell and gene therapy, vaccines) and two businesses (CSL Behring and Seqirus).

Masimo (NASDAQ: MASI) today announced the findings of an abstract presented at ANESTHESIOLOGY 2021 in San Diego, in which Drs. Anita Kulkarni and Arti Dalal at the Rajiv Gandhi Cancer Institute in New Delhi, India evaluated the use of noninvasive, continuous Masimo PVi® as part of goal-directed fluid therapy (GDFT) to guide intraoperative fluid administration during major oncosurgery in which lung ultrasonography (LUS) is used to diagnose extravascular lung water (EVLW).